Aquestive Therapeutics, Inc. (AQST) › Cost of RevenueAquestive Therapeutics, Inc. (AQST) — Cost of RevenueAnnual figures by period end, from SEC filings.2019-12-31: $20.36M2020-12-31: $12.96M2022-12-31: $19.39M2023-12-31: $20.83M2024-12-31: $17.87M2025-12-31: $18.55M$18.55M2019-12-31Cost of Revenue (USD)2025-12-31Period endedCost of RevenueChange YoYSource filing2025-12-31$18.55M+3.8%2026-03-04From 2025-01-012024-12-31$17.87M-14.2%2026-03-04From 2024-01-012023-12-31$20.83M+7.5%2025-03-05From 2023-01-012022-12-31$19.39M—2024-03-05From 2022-01-012020-12-31$12.96M-36.3%2021-03-09From 2020-01-012019-12-31$20.36M—2021-03-09From 2019-01-01Other metrics: RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)